Intellex Acquires Expert by Big Village

We're thrilled to announce that Intellex has acquired Expert by Big Village, effective March 22, 2024. This strategic move enhances our capabilities and strengthens our commitment to delivering exceptional solutions to our customers.

Stay tuned for more updates on how this acquisition will benefit our clients and experts.

For inquiries or more information, please contact us at info@intellex.com.

×

Expert Details

Molecular Psychiatry and Neuroscience, Neuropharmacology, Cancer Immunotherapy

ID: 731256 United Kingdom

Request Expert

Expert has combined his extensive expertise in molecular biology, immunology, molecular neuroscience and psychiatry, and cancer biology to develop a new avenue in the discovery of suitable molecular targets for complex treatment of neurodevelopmental disorders (e.g. ADHD). The new treatment strategies are designed to avoid adverse effects while taking care not only for managing the symptoms of the disorders but to result in their cure.

At the moment, some novel and exciting unpublished strategies for treatment of ADHD are considered by Expert. He obtained in vitro data supporting the idea that such treatment with naturally existing molecules will result in better development of children’s brain and possibly take care for removing the insomnia from which ADHD patients suffer. Expert is particularly interested in pursuing this new treatment strategy in animal models and in patients.

He has also consulted on applicability of different nanoparticles carriers of drugs in neorodevelopmental and other neurological disorders. This is a very important issue because in general all drugs and their carriers are tested for toxicity while not taking good care for their potential adverse effects by a complex assessment of physiological alterations that might occur.

He has combined his extensive expertise in molecular biology, immunology, molecular neuroscience and cancer biology to develop a new avenue in the discovery of suitable molecular targets for treatment of different tumour types which result specifically in killing the cancer cells while not having significant effect on non-malignant ones. These strategies have been tested both in vitro and in vivo showing a great promise. Some of the designed peptides have been filed for a patent application.

 Highly creative science leader with over 20 year experience in life and pharmaceutical sciences with particular emphasis on protein chemistry, immunotherapeutics, neuroscience/molecular psychiatry, working for organisations in Europe, North America and Middle East, focused on innovation and development of new therapeutics.
 Outstanding manager with unique profile, combining strong technical and teaching/training expertise, innovatively leading multi-cultural teams to deliver growth solutions.
 A proven track record in discovery of new therapeutic targets and development of new treatments.
 Influencing and growing life science publishing business and implementing a consumer-focused approach.

CORE QUALIFICATIONS & STRENGTHS

 Effective and innovative project and people management
 Strategic agility, project planning and budgeting
 Product development: discovery of new therapeutic targets and drug development
KEY ACHIEVEMENTS
PROJECT MANAGEMENT
Led and successfully completed a number of projects focused on:
 Design and assessment of oral formulations of therapeutic antibodies for treatment of infections and disorders of the gastrointestinal tract
 Signalling/molecular mechanisms underlying inflammatory responses in neuropsychiatric disorders and identification of suitable therapeutic targets for drug development
 Design of peptide adjuvants for targeted sensitisation of certain tumours to immunoclearance
 Currently organizing clinical trial


Consulted on interrelationship between complement system and clock genes in ADHD as a strategy for treatment of ADHD patients.He consulted on biomarkers for the response to drug treatment of major depression, signalling/molecular mechanisms underlying responses in major depression and identification of suitable therapeutic targets for drug development.Consulted on different nanoparticles designed as drug carriers in their applicability for treatment of psychiatric disorders without compromising neurogenesis and neurodevelopment.Consulted on methods employed in pharmaceutical and cosmetic industries, and academic research for development of robotised testing platforms.Consulting on continuous increase in reputation and sales of periodicals.

Education

Year Degree Subject Institution
Year: 1999 Degree: PhD Subject: Molecular Cell Biology Institution: Institute of Molecular Biology, Bulgarian Academy of Sciences
Year: 1990 Degree: MSc Subject: Biotechnology Institution: Faculty of Biology, Sofia University, Bulgaria
Year: 1989 Degree: BSC Subject: Biotechnology Institution: Faculty of Biology, Sofia University, Bulgaria

Work History

Years Employer Title Department
Years: 2012 to Present Employer: Undisclosed Title: Director Department:
Responsibilities:
He is responsible for the general running of the company, provides editorial support for scientific journals and design of new formulations for skin care products.
Years Employer Title Department
Years: 2010 to Present Employer: Undisclosed Title: Editor-in-Chief Department:
Responsibilities:
Responsible for identifying suitable topics for volumes of the Advances in Protein Chemistry and Structural Biology in order to increase the reputation and sales of this periodical, assessing and editing contributions to the journal.
Years Employer Title Department
Years: 2011 to 2012 Employer: Rostock University Title: Visiting Consultant Department:
Responsibilities:
Consultations on interrelationship between complement system and clock genes.
Years Employer Title Department
Years: 2010 to 2013 Employer: College of Medicine, Swansea University Title: Lecturer Department: Neuropsychopharmacology
Responsibilities:
Responsible for managing research projects in molecular psychiatry and psychopharmacology, teaching students, supervising academic related staff, undergraduate and postgraduate students working in the laboratory.
Years Employer Title Department
Years: 2007 to 2009 Employer: Cardiff University Title: MRC New Investigator Award Department: School of Medicine
Responsibilities:
Identified molecular mechanisms that regulate resistance of brain tumors to immuno- and chemotherapy and designed therapeutic peptides for their sensitisation to clearance by immune system.
Years Employer Title Department
Years: 2003 to 2007 Employer: Cardiff University Title: Research Fellow Department: School of Medicine
Responsibilities:
Discovered novel roles of CD59 in immunotherapy.
Years Employer Title Department
Years: 1999 to 2003 Employer: London Research Institute Title: Research Fellow Department: Human Cytogenetics Laboratory, Cancer Research UK
Responsibilities:
Human Cytogenetics Laboratory, Cancer Research UK

Discovered new mechanisms regulating the accumulation of amyloid plaques and control of expression of the Major Histocompatibility Complex in human.
Years Employer Title Department
Years: 1991 to 1999 Employer: Bulgarian Academy of Sciences Title: Research Associate Department: Cell Proliferation and Differentiation Laboratory, Institute of Molecular Biology
Responsibilities:
Revealed new mechanisms involved in the dynamic of the genome during cell cycle and nuclear compartmentalisation.

Government Experience

Years Agency Role Description
Years: 2011 to 2011 Agency: Medical Research Council, UK Role: Grant reviewer Description: He served as a grant reviewer.
Years: 2013 to 2013 Agency: Agency for Health Quality and Assessment of Catalonia (AHQAC), Barcelona, Spain Role: Grant reviewer Description: He served as a reviewer on three grant applications.

International Experience

Years Country / Region Summary
Years: 2011 to 2012 Country / Region: Germany Summary: He carried out consultations on manipulation of the interrelationship between complement system and clock genes in ADHD as a strategy for a therapy.
Years: 2012 to 2013 Country / Region: Kuwait Summary: He consulted on biomarkers for the response to drug treatment of major depression. Further analyses on signalling/molecular mechanisms underlying responses in major depression and identification of suitable therapeutic targets for drug development were undertaken.
Years: 2010 to 2012 Country / Region: Bulgaria Summary: He consulted on different nanoparticles designed as drug carriers in their applicability for treatment of psychiatric disorders without compromising neurogenesis and neurodevelopment.
Years: 2013 to 2013 Country / Region: Switzerland Summary: He consulted on methods employed in pharmaceutical and cosmetic industries, and academic research for development of robotised testing platforms.
Years: 2006 to 2006 Country / Region: Russia Summary: He consulted on satellite DNA binding drugs.

Career Accomplishments

Associations / Societies
- Member of the New York Academy of Sciences
- Member of the Network of Healthcare Advisors
- Member of the International Complement Society
Professional Appointments
TECHNICAL EXPERTISE
 Cell cultures, including primary and stem cells
 Cytotoxicity and immunocytotoxicity assays
 ELISA
 Design of oral and i.v. formulations of immunotherapeutics
 DNA/RNA extraction and manipulation
 Design and manipulation of recombinant nucleic acids
 PCR/qPCR
 Biological characterisation of nanoparticles for drug delivery
 Epigenetics
 Molecular cloning and transfection
 Protein expression, purification and characterisation of recombinant and native proteins
 Protein-DNA interactions (Chromatin Immunoprecipitation)
 Phage-display library for selection of therapeutic peptides and identification of receptors
 Design of therapeutic peptides/proteins for immunotherapy
 Blood cells purification, stimulation and analysis
 Flow cytometry
 Immunocytochemistry and immunohistochemistry
 Fluorescent in situ hybridisation
Awards / Recognition
Medical Research Council UK, New Investigator Award
Publications and Patents Summary
Published over 60 peer-reviewed articles in well-respected and highly reputable journals plus several invited talks and plenary talks and book chapter.
Filed one patent application.

Additional Experience

Expert Witness Experience
BUSINESS DEVELOPMENT AND CONSULTING EXPERIENCE
 Developed successful projects for a new private molecular psychiatry laboratory for a client in Kuwait
 Improved the reputation and sales of Advances in Protein Chemistry and Structural Biology, Elsevier, New York
 Reviewed grants for the Medical Research Council UK, Alzheimer’s Society UK and the Agency for Health Quality and Assessment of Catalonia (AHQAC), Barcelona, Spain
 Consulted on suitability of different nanoparticles designed as drug carriers for treatment of psychiatric disorders without compromising neurogenesis and neurodevelopment
Training / Seminars
Editor of a number of books, including Inflammation in Neuropsychiatric Disorders, Protein-Nucleic Acids Interactions, Organisation of Chromosomes, Protein Structure and Diseases.
Marketing Experience
Expert's background and expertise suits perfectly pharmaceutical industries interested in the development of therapeutics for the treatment of neurodevelopmental and neurodegenerative disorders, and for cancer immunotherapy. He has also experience in consulting companies for the development of robots for use in chemical, pharmaceutical, and biotechnology industries and academic research. Running his own company in scientific publishing, antibody sales, and development of skin care products, he has developed customer focused attitude with excellent communication, leadership and influencing skills. Being editor-in-chief of a scientific periodical, Expert considerably increased the reputation and sales of this journal.
Other Relevant Experience
- research and advise on alterations in signalling pathways/metabolism in psychiatric, neurological disorders and tumours and ways of exploring these alterations for therapeutic benefit
- design of processes for creation of robotised platforms for pharmaceutical and cosmetic industries, and academic research
- applicability of drug carriers for treatment of developmental psychiatric disorders

TEAM LEADERSHIP
 Proven ability to manage through others.
 Strong decision making and problem solving skills
 Able to motivate and lead others in a team environment

Language Skills

Language Proficiency
English He is fluent in English language
Bulgarian He is fluent in Bulgarian language
Russian He is fluent in speaking and reading, and intermediate in writing in Russian language

Fields of Expertise

Request Expert

Dev Tool:

Request: expert/molecular-psychiatry-and-neuroscience-neuropharmacology-cancer-immunotherapy
Matched Rewrite Rule: expert/([^/]+)(?:/([0-9]+))?/?$
Matched Rewrite Query: experts=molecular-psychiatry-and-neuroscience-neuropharmacology-cancer-immunotherapy&page=
Loaded Template: single-experts.php